Dementia and Alzheimer's Care Options: Medical Management and Support Services

Dementia and Alzheimer's disease represent a spectrum of progressive neurological conditions that affect an estimated 6.7 million Americans age 65 and older, according to the Alzheimer's Association 2023 Alzheimer's Disease Facts and Figures report. Medical management spans pharmacological intervention, structured care planning, and a tiered system of support services ranging from home-based assistance to memory care facilities. This page covers the clinical definitions, structural components of care delivery, causal and risk frameworks, classification of dementia subtypes, contested tradeoffs in care, and practical reference tools for understanding the full landscape of available options.

• Definition and Scope
• Core Mechanics or Structure
• Causal Relationships or Drivers
• Classification Boundaries
• Tradeoffs and Tensions
• Common Misconceptions
• Checklist or Steps (Non-Advisory)
• Reference Table or Matrix
• References

Definition and Scope

Dementia is a clinical syndrome, not a single disease, characterized by a decline in cognitive function severe enough to interfere with daily life. The World Health Organization (WHO) defines dementia as a syndrome in which there is deterioration in memory, thinking, behavior, and the ability to perform everyday activities. Alzheimer's disease accounts for 60–80% of all dementia cases, per the Alzheimer's Association.

The scope of medical management extends beyond memory symptoms alone. It encompasses neuropsychiatric symptom control, functional capacity preservation, caregiver support coordination, and advance care planning. The National Institute on Aging (NIA) classifies Alzheimer's disease management into three overlapping domains: pharmacological treatment, non-pharmacological interventions, and care coordination. Regulatory oversight of care providers falls under the Centers for Medicare & Medicaid Services (CMS), which establishes Conditions of Participation for skilled nursing facilities, home health agencies, and hospice providers delivering dementia-related services.

For a broader orientation to the health services landscape in which dementia care is embedded, see Medical and Health Services: Topic Context.

Core Mechanics or Structure

Dementia care operates through a phased model aligned to disease progression. The NIA Alzheimer's Disease Care Planning framework identifies three broad stages — early, middle, and late — each requiring distinct clinical and support strategies.

Early Stage: Cognitive assessment tools, including the Mini-Mental State Examination (MMSE) and the Montreal Cognitive Assessment (MoCA), establish baseline function. Diagnostic confirmation typically involves neuroimaging (MRI or CT), neuropsychological testing, and laboratory panels to rule out reversible causes. The Alzheimer's Association Dementia Care Practice Recommendations specify that care planning at this stage should include disclosure of diagnosis, advance directive completion, and medication initiation if appropriate.

Two classes of FDA-approved medications address Alzheimer's symptoms:
- Cholinesterase inhibitors (donepezil, rivastigmine, galantamine) — indicated for mild-to-moderate stages
- NMDA receptor antagonists (memantine) — indicated for moderate-to-severe stages
- Anti-amyloid monoclonal antibodies (lecanemab, approved by FDA in 2023 under accelerated approval) — indicated for early symptomatic Alzheimer's disease with confirmed amyloid pathology

Middle Stage: Behavioral and psychological symptoms of dementia (BPSD) — including agitation, psychosis, and sleep disturbance — become the primary management focus. Non-pharmacological interventions endorsed by the American Geriatrics Society (AGS) and the NIA include structured activity programming, music therapy, and environmental modification. When pharmacological treatment of BPSD is required, the FDA's black-box warning on atypical antipsychotics used in elderly patients with dementia requires documented informed consent.

Late Stage: Palliative and comfort-focused care replaces disease-modifying interventions. CMS Conditions of Participation at 42 CFR §418 govern hospice services, which become eligible when a physician certifies a prognosis of six months or less if the disease follows its expected course. For details on end-of-life care structure, see Hospice and Palliative Care for Seniors.

Coordination between the primary care physician, geriatric medicine specialists, neurologists, social workers, and family caregivers forms the operational spine of dementia care delivery.

Causal Relationships or Drivers

Alzheimer's disease pathology centers on the accumulation of amyloid-beta plaques and tau neurofibrillary tangles, resulting in synaptic loss and neuronal death. The NIA's molecular framework identifies this cascade as beginning 10–20 years before clinical symptoms appear.

Established risk factors, as classified by the Lancet Commission on Dementia Prevention, Intervention, and Care (2020), include 12 modifiable contributors responsible for approximately 40% of dementia cases globally. These include:

• Mid-life hypertension — associated with elevated vascular dementia risk
• Hearing loss — the single largest modifiable risk factor identified, accounting for 8% of attributable cases
• Physical inactivity, smoking, obesity, depression, diabetes, low educational attainment, social isolation, excessive alcohol consumption, traumatic brain injury, and air pollution

Non-modifiable risk factors include advanced age (risk doubles approximately every five years after age 65), female sex (women account for approximately two-thirds of Alzheimer's cases in the US per the Alzheimer's Association), and the APOE ε4 allele, which is the strongest known genetic risk factor for late-onset Alzheimer's.

Vascular contributors — including atrial fibrillation, stroke history, and poorly controlled hypertension — drive mixed and vascular dementia subtypes. For cardiovascular risk management, see Senior Cardiology Services. Chronic disease management frameworks that address hypertension and diabetes are explored at Chronic Disease Management for Seniors.

Classification Boundaries

Dementia subtypes carry distinct pathological mechanisms, clinical presentations, and care implications:

Source: NIA Dementia Information Page; Alzheimer's Association Dementia Types

Mild Cognitive Impairment (MCI) occupies a boundary state between normal aging and dementia. Approximately 10–20% of adults age 65 and older have MCI, per the NIA, and roughly 10–15% of individuals with MCI progress to dementia per year. MCI does not meet the diagnostic threshold for dementia because functional independence is preserved. Cognitive assessment tools for seniors provide the clinical instruments used to differentiate MCI from dementia and from age-associated memory impairment.

Tradeoffs and Tensions

Dementia care presents contested tradeoffs across clinical, ethical, and systemic dimensions.

Antipsychotic use in BPSD: The FDA black-box warning issued for atypical antipsychotics (2005, reiterated for conventional antipsychotics in 2008) documents a 1.6–1.7 times increased mortality risk when these drugs are used in elderly patients with dementia. CMS tracks antipsychotic prescribing rates in nursing facilities through the Nursing Home Compare quality reporting system as a public quality indicator. Yet behavioral symptoms can endanger both the person with dementia and caregivers, creating genuine clinical tension when non-pharmacological interventions prove insufficient.

Anti-amyloid therapy access and eligibility: Lecanemab (brand name Leqembi), granted full FDA approval in July 2023, targets early Alzheimer's with confirmed amyloid pathology. CMS coverage, finalized in July 2023, limits reimbursement to patients enrolled in qualifying registries, effectively restricting access based on participation requirements. This creates a structural equity gap between academic medical centers capable of registry participation and community-based care settings.

Residential placement timing: Families and clinicians disagree on when residential memory care becomes clinically appropriate versus when home-based care remains viable. No federal standard defines a mandatory placement threshold. State licensing standards under respective Departments of Health regulate memory care unit requirements separately across all 50 states.

Person-centered versus safety-based care: The Centers for Disease Control and Prevention (CDC)'s Healthy Brain Initiative endorses person-centered care frameworks that preserve autonomy, including risk tolerance around mobility and independent decision-making. This is in tension with institutional risk management priorities in licensed care settings, where liability exposure shapes care protocols.

Common Misconceptions

Misconception 1: Dementia is a normal part of aging.
Dementia is a pathological process, not an inevitable outcome of aging. The NIA distinguishes between age-related memory change (slower processing, word-finding difficulties that do not worsen significantly) and dementia, which involves progressive functional decline. The majority of individuals who reach age 85 do not develop dementia.

Misconception 2: Alzheimer's disease affects only memory.
Alzheimer's disease produces a broad neuropsychiatric syndrome including language disruption (aphasia), visuospatial impairment, behavioral disinhibition, and disrupted sleep architecture. The Alzheimer's Association diagnostic criteria (2018 NIA-AA Research Framework) define the disease along a biological continuum independent of clinical symptoms.

Misconception 3: Nothing can be done once dementia is diagnosed.
FDA-approved pharmacological agents modify symptoms and, in the case of anti-amyloid therapies, address underlying pathology in early stages. Non-pharmacological interventions — structured activity, environmental modification, caregiver training — have documented efficacy for BPSD management per the AGS and NIA. Palliative care and advance care planning preserve quality of life across all stages.

Misconception 4: Medicare covers all dementia care costs.
Medicare Part A and Part B cover medically necessary services including physician visits, diagnostic testing, and skilled nursing facility stays following a qualifying hospitalization. Medicare does not cover custodial care — the non-medical assistance with activities of daily living that constitutes the majority of long-term dementia care costs. Medicaid is the primary payer for custodial nursing home care for eligible individuals. See Medicare Coverage for Senior Health Services and Medicaid and Dual Eligibility for Seniors for coverage structure.

Misconception 5: Family caregivers do not need clinical support.
The AARP Public Policy Institute estimates that 83% of long-term care help received by older adults in the US comes from unpaid caregivers, with dementia caregiving associated with elevated rates of depression, anxiety, and physical health decline in the caregiver. Caregiver assessment is a component of comprehensive dementia care per the NIA guidelines and CMS-funded programs under the National Family Caregiver Support Program (OAA Title III-E).

Checklist or Steps (Non-Advisory)

The following is a reference sequence of clinical and administrative steps commonly associated with dementia diagnosis, staging, and care planning. This reflects documented frameworks from the NIA and Alzheimer's Association — it is a descriptive map of typical processes, not a clinical recommendation.

Step 1 — Initial Cognitive Screening
- Administration of standardized screening instruments (MMSE, MoCA, or Mini-Cog)
- Documentation of functional status using ADL/IADL scales
- Informant interview to capture behavioral and functional change over time

Step 2 — Diagnostic Workup
- Laboratory panel: CBC, CMP, thyroid function, B12, folate, RPR (to exclude reversible causes per NIA guidance)
- Neuroimaging: structural MRI preferred; CT when MRI is contraindicated
- Referral to senior neurology services or neuropsychology for complex or atypical presentations

Step 3 — Diagnosis Disclosure and Care Planning
- Formal disclosure meeting including the patient and designated support persons
- Completion of advance directives and healthcare proxy designation
- Referral to advance care planning for seniors resources

Step 4 — Pharmacological Management Initiation
- Cholinesterase inhibitor prescribing for mild-to-moderate Alzheimer's (donepezil, rivastigmine, galantamine)
- Memantine addition for moderate-to-severe stages
- Medication reconciliation review — polypharmacy is a primary safety concern; senior medication management frameworks apply

Step 5 — Non-Pharmacological Intervention Planning
- Structured activity programming tailored to cognitive stage
- Environmental safety assessment (fall hazards, door alarms, stove safety)
- Caregiver education enrollment (Alzheimer's Association or NIA-funded programs)

Step 6 — Care Setting Evaluation
- Assessment of home care feasibility using functional dependency scoring
- Evaluation of home health care services for seniors
- Memory care community eligibility assessment if home care is no longer viable

Step 7 — Ongoing Monitoring and Transition
- Quarterly to semi-annual cognitive and functional reassessment
- BPSD symptom monitoring using validated scales (NPI, CMAI)
- Transition planning to palliative care when disease reaches advanced stage

Step 8 — End-of-Life Care Integration
- Hospice eligibility determination under 42 CFR §418 criteria
- Comfort-focused care plan with family communication protocol
- Bereavement support coordination for caregivers

Reference Table or Matrix

Dementia Care Settings: Structural Comparison